European Medicines Agency (EMEA) recommends revocation of marketing authorisation for bufexamac containing medicines.

Last Updated on

April 27, 2010 – From an announcement by the EMEA we learn that bufexamac-containing medicines were to be taken off EU markets because of high risk of contact allergies.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that marketing authorisations for bufexamac- containing medicines be revoked. The CHMP recommendations follow a scientific review, which identified a high risk of sometimes serious contact allergic reactions with bufexamac. The risk was even higher in patients with pre-disposing conditions, such as certain forms of eczema, for which bufexamac is frequently prescribed.

Furthermore, the allergic reactions caused by bufexamac are very similar to the disease being treated, which may lead to a potential delay in the correct diagnosis and treatment of patients. It is also likely that the difficulty to differentiate between a treatment failure and an allergic reaction has led to the cases of contact allergic reaction being underreported. In addition to this, the data to support the effectiveness of bufexamac are very limited, so the Committee concluded that, based on the available information, the benefits of the bufexamac-containing medicines did not outweigh its risks and recommended that they be taken off the market across the European Union.

Bufexamac is a non-steroidal anti-inflammatory drug (NSAID), used as topical formulations to treat dermatological diseases (eczema and dermatitis) and proctological conditions (haemorrhoids and anal fissure). Bufexamac-containing medicines have been available in EU Member States since the 1970s. It had been known for some time that bufexamac may trigger contact allergic reactions. This has led to restrictions on the use of the medicines in a number of EU countries over the years. The latest review of the benefits and risks of bufexamac was completed in December 2009 by the German medicines regulatory authority, which decided to withdraw all marketing authorisations for bufexamac in Germany. As required by EU legislation, the German authority informed the CHMP of its regulatory action, so that the Committee could prepare an opinion on whether the marketing authorisations for these medicines should be revoked all over the EU or whether they should be maintained, changed or suspended.

Based on the available data the CHMP concluded that the marketing authorisations for Bufexamac should be revoked. The CHMP’s opinion has now been sent to the European Commission for the adoption of a decision.

Previously, medicines containing bufexamac have been authorised as Parfenac, Bufal, Calmaderm, Fansamac, Mastu, Parfenoide, Proctosan or other trade names in Austria, Bulgaria, the Czech Republic, France, Hungary, Italy, Latvia, Lithuania, Luxembourg, Portugal, Romania and Slovakia. They may be available as creams, rectal ointments and suppositories. Because of the restrictions placed on these medicines over the years, their use in the EU is limited.

Please read his press release, together with other information on the work of the European Medicines Agency, on the Agency’s website at www.ema.europa.eu.

Tags: , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Citizen science and paddle surf to study microplastic pollution in Barcelona's coastline February 27, 2020
    A team of the University of Barcelona has studied for the first time the presence of microplastics in the coasts of Barcelona, with the collaboration of the citizens gathering scientific samples. The study, published in the journal Science of Total Environment, is a pioneer citizen science study worldwide, since it analyses a hard-access area for […]
  • Celiac disease might be cured by restoring immune tolerance to gliadin February 27, 2020
    Celiac disease affects 0.3-2.4% of people in most countries world-wide, and approx. 2% in Finland. Celiac patients suffer from a variety of symptoms, typically intestinal complaints, such as diarrhea, but are often symptom-free. Immunologist Tobias Freitag co-developed and tested nanoparticles containing gliadin for the immunomodulatory treatment of celiac disease in Professor Seppo Meri's research group […]
  • Abnormal growth of bacterial cells could be linked to anti-microbial resistance February 27, 2020
    Scientists from the University of Surrey have identified mutations in a gene in an Escherichia coli (E.coli) model that could help explain a form of anti-microbial resistance (AMR) known as 'persistence'.
  • Study unravels how our immune system deals with fungal and viral infections February 27, 2020
    The body's immune response to fungal infections changes when a patient is also infected by a virus, according to new research which investigated the two types of infection together for the first time.
  • How the brain separates words from song February 27, 2020
    The perception of speech and music -- two of the most uniquely human uses of sound -- is enabled by specialized neural systems in different brain hemispheres adapted to respond differently to specific features in the acoustic structure of the song, a new study reports.
Top